PES2020-Prosj.etabl.støtte H2020
Development of a novel drug for the treatment of patients with glycolytic cancers
Arctic Pharma´s overall goal is to bring a new class of cancer medicine to the marked which targets the energy metabolism of many aggressive cancer types.
In particular, Arctic Pharma AS has developed small molecular inhibitors that are designed to target the molecule lactate dehydrogenase (LDH),...